Get started
Autolus Therapeutics Plc Sponsored ADRAutolus Therapeutics Plc Sponsored ADRAutolus Therapeutics Plc Sponsored ADR

Autolus Therapeutics Plc Sponsored ADR

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasDiscussionsTechnicalsForecastSeasonalsOptionsETFs

AUTL chart


Full chart

AUTL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪428.49 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.86 USD
Net income (FY)
‪−220.75 M‬ USD
Revenue (FY)
‪10.12 M‬ USD
Shares float
‪240.33 M‬
Beta (1Y)
1.32

About Autolus Therapeutics Plc Sponsored ADR


Sector
Health Technology
Industry
Biotechnology
CEO
Christian Martin Itin
Website
autolus.com
Headquarters
London
Founded
2018
ISIN
US05280R1005
FIGI
BBG00KVT05R6
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Check out other big names from the same industry as AUTL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AUTL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs with AUTL exposure


IBB
iShares Biotechnology ETF
Weight
0.03%
Market value
‪1.62 M‬
USD
SBIO
ALPS Medical Breakthroughs ETF
Weight
0.22%
Market value
‪200.62 K‬
USD
BTEE
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.03%
Market value
‪199.30 K‬
USD
BTEC
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.03%
Market value
‪199.30 K‬
USD
CANC
Tema Oncology ETF
Weight
0.23%
Market value
‪186.48 K‬
USD
SBIO
Invesco NASDAQ Biotech UCITS ETF
Weight
0.03%
Market value
‪105.90 K‬
USD
BBC
Virtus LifeSci Biotech Clinical Trials ETF
Weight
0.47%
Market value
‪85.21 K‬
USD
QQQS
Invesco NASDAQ Future Gen 200 ETF
Weight
0.48%
Market value
‪49.10 K‬
USD
203780
MIRAE ASSET TIGER NASDAQ BIO ETF
Weight
0.03%
Market value
‪13.80 K‬
USD
IBBQ
Invesco Nasdaq Biotechnology ETF
Weight
0.03%
Market value
‪12.16 K‬
USD
BIB
ProShares Ultra Nasdaq Biotechnology
Weight
0.02%
Market value
‪11.50 K‬
USD

Explore more ETFs